0001299130-21-000216 | 10-Q | XBRL Viewer | Pacific Biosciences OF California INC

Label	Element	Value
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Contract Termination	pacb_ContractTermination
Debt Instrument, Conversion Rate, Shares Issued Per Stated Amount	pacb_DebtInstrumentConversionRateSharesIssuedPerStatedPrincipalAmount	22.9885
Operating Lease, Right-of-Use Asset, Amortization	pacb_OperatingLeaseRightOfUseAssetAmortization	$ 2,403,000
Operating Lease, Right-of-Use Asset, Amortization	pacb_OperatingLeaseRightOfUseAssetAmortization	2,127,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	8,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	31,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	52,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	91,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	91,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	4,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	96,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	6,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	106,000
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	106,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	8,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	54,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	62,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	63,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	8,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	12,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	20,000
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments	pacb_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	$ 21,000
Number of Petitions	pacb_NumberOfPetitions	2
Income tax benefit from reduction in deferred tax assets valuation allowance	pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance	$ 92,200,000
Income tax benefit from reduction in deferred tax assets valuation allowance	pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance	94,800,000
Amortization of intangible assets and research development expense	pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense	154,000
Contractual Interest Expense	pacb_ContractualInterestExpense	3,375,000
Contractual Interest Expense	pacb_ContractualInterestExpense	8,438,000
Pro forma adjustment related to acquiree's acquisition-related costs	pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts	16,700,000
Additional Liability Associated With Indemnification Obligations	pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations	$ 0
Share Based Compensation Arrangements By Share Based Payment Awards Number Of Active Plans	pacb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardsNumberOfActivePlans	3
Stock-based compensation expense excluded from consideration transferred	pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred	$ 18,923,000
Long Term Restricted Cash Fair Value Disclosure	pacb_LongTermRestrictedCashFairValueDisclosure	4,560,000
Long Term Restricted Cash Fair Value Disclosure	pacb_LongTermRestrictedCashFairValueDisclosure	4,560,000
Long Term Restricted Cash Fair Value Disclosure	pacb_LongTermRestrictedCashFairValueDisclosure	3,500,000
Long Term Restricted Cash Fair Value Disclosure	pacb_LongTermRestrictedCashFairValueDisclosure	$ 3,500,000
Debt Instrument, Redemption Price, Consecutive Trading Days	pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays	30 days
Increase (Decrease) in Deferred Gain from Reverse Termination Fee	pacb_IncreaseDecreaseInDeferredGainFromReverseTerminationFee	$ 98,000,000
Proceeds from (Repayments of) Contract Termination	pacb_ProceedsFromRepaymentsOfContractTermination	(52,000,000)
Proceeds from (Repayments of) Contract Termination	pacb_ProceedsFromRepaymentsOfContractTermination	$ 34,000,000
Debt Instrument, Redemption Price, Trading Days	pacb_DebtInstrumentRedemptionPriceTradingDays	20 days
Business Combination, Recognized Identifiable Assets Operating lease right-of-use assets, net Acquired and Liabilities Assumed Operating Lease Right of use assets Net	pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet	$ 18,095,000
Exchange ratio	pacb_ExchangeRatio	0.259204639
Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted	pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	(0.25)
Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted	pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	(0.21)
Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted	pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	(0.97)
Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted	pacb_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	(0.24)
Issuance of common stock in Private Placement, net of issuance costs shares	pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares	11,215,000
Issuance of common stock in Private Placement, net of issuance costs shares	pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares	11,215,000
Issuance of common stock in Private Placement, net of issuance costs shares	pacb_IssuanceOfCommonStockInPrivatePlacementNetOfIssuanceCostsShares	11,214,953
Short-Term Restricted Cash Fair Value Disclosure	pacb_ShortTermRestrictedCashFairValueDisclosure	$ 500,000
Short-Term Restricted Cash Fair Value Disclosure	pacb_ShortTermRestrictedCashFairValueDisclosure	500,000
Short-Term Restricted Cash Fair Value Disclosure	pacb_ShortTermRestrictedCashFairValueDisclosure	836,000
Short-Term Restricted Cash Fair Value Disclosure	pacb_ShortTermRestrictedCashFairValueDisclosure	$ 836,000
Weighted average number of stock options	pacb_WeightedAverageNumberOfStockOptions	7,754,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	$ 11,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	294,834,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	294,845,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	11,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	294,834,000
Issuance of common stock in Private Placement, net of issuance costs	pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts	294,845,000
Proceeds from issuance of common stock under equity offerings, net of issuance costs	pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts	294,846,000
Proceeds from issuance of common stock under equity offerings, net of issuance costs	pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts	93,788,000
Debt Instrument, Stated Principal Amount for Conversion Rate	pacb_DebtInstrumentStatedPrincipalAmountForConversionRate	$ 1,000

Termination of Merger with Illumina (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		9 Months Ended
	Feb. 28, 2021	Apr. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2021
Merger Termination [Line Items]
Continuation Advances			$ 34.0	$ 18.0
Possible Continuation Advances payable			$ 52.0
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party					2 years
Equity or debt financing that must be raised in a single transaction					$ 100.0
Continuation Advances paid	$ 52.0
Advisor fees paid		$ 6.0

Balance Sheet Components (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($)
Balance Sheet Components [Line Items]
May 1 annual decrease to long-term restricted cash	$ 0.5
Deferred service revenue, noncurrent, recognition period	5 years

Invitae Collaboration (Narrative) (Details)	Jan. 12, 2021
Development and Commercialization Agreement Transactions [Line Items]
Development program term	60 months
Preferential pricing period for each program product	4 years

Print Document View Excel Document
Notes Details Invitae Collaboration (Narrative) (Details) Termination of Merger with Illumina (Narrative) (Details) Balance Sheet Components (Narrative) (Details) Uncategorized Uncategorized Items - pacb-20210930x10q_htm.xml All Reports